APA (7th ed.) Citation

Samantha Cohen, Melissa Schwartz, Peter Dottino, & Ann Marie Beddoe. (2019). Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer. BMC.

Chicago Style (17th ed.) Citation

Samantha Cohen, Melissa Schwartz, Peter Dottino, and Ann Marie Beddoe. Use of a Multi-drug Regimen Gemcitabine, 5-fluorouracil, Irinotecan, Cisplatin, Bevacizumab, Docetaxel, and Cyclophosphamide (GFIP/BDC) for Heavily Pretreated Relapsed Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer. BMC, 2019.

MLA (9th ed.) Citation

Samantha Cohen, et al. Use of a Multi-drug Regimen Gemcitabine, 5-fluorouracil, Irinotecan, Cisplatin, Bevacizumab, Docetaxel, and Cyclophosphamide (GFIP/BDC) for Heavily Pretreated Relapsed Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer. BMC, 2019.